🔎 Trials Near Me

Utama › Mieloma Pelbagai › Ohio › Cleveland

Kajian klinikal Mieloma Pelbagai di Cleveland, OH

16 kajian untuk Mieloma Pelbagai sedang mencari peserta di lokasi dalam dan sekitar Cleveland (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.

Teks kajian rasmi (Bahasa Inggeris)

Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →

A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events

Mengambil pesertaFasa 2
  • University Hospitals Cleveland Medical Center, Cleveland
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06500884

A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

Mengambil pesertaFasa 2
  • Cleveland Clinic, Cleveland
Umur 18 hingga 80 · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07149857

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

Mengambil pesertaFasa 3
  • University Hospitals Cleveland Medical Center, Cleveland
  • Cleveland Clinic Main Campus, Cleveland
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT05552222

A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma

Mengambil pesertaFasa 1/2
  • Research Site, Cleveland
Umur 18 ke atas · Semua jantina · Dikemas kini 27 Ogo 2026 · NCT07681596

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Mengambil pesertaFasa 3
  • MetroHealth Medical Center, Cleveland
Umur 18 ke atas · Semua jantina · Dikemas kini 19 Ogo 2026 · NCT04566328

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

Mengambil pesertaFasa 1
  • Cleveland Clinic - Taussig Cancer Institute, Cleveland
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Ogo 2026 · NCT05651932

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

Mengambil pesertaFasa 3
  • Research Site, Cleveland
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Ogo 2026 · NCT07764978

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Mengambil pesertaFasa 3
  • Seidman Cancer Center-University Hospitals Cleveland Medical Center, Cleveland
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Jun 2026 · NCT05243797

Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring

Mengambil pesertaKajian pemerhatian
  • University Hospitals Seidman Cancer Center, Cleveland
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Feb 2026 · NCT05974150

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
  • Cleveland Clinic, Cleveland
Umur 40 ke atas · Semua jantina · Dikemas kini 20 Jan 2026 · NCT05366881

CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

Mengambil pesertaFasa 1
  • Cleveland Clinic, Cleveland
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2025 · NCT05722418

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Mengambil pesertaFasa 1/2
  • University Hospitals Cleveland, Cleveland
Umur 18 ke atas · Semua jantina · Dikemas kini 3 Jun 2025 · NCT06119685

LMY-920 for Treatment of Relapsed or Refractory Myeloma

Mengambil pesertaFasa 1
  • University Hospitals Seidman Cancer Center, Cleveland
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Okt 2024 · NCT05546723

Kajian Mieloma Pelbagai di bandar lain

Kajian lain di Cleveland

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.